MANNKIND CORP (MNKD) Fundamental Analysis & Valuation

NASDAQ:MNKD • US56400P7069

Current stock price

2.28 USD
-0.02 (-0.87%)
At close:
2.2865 USD
+0.01 (+0.29%)
After Hours:

This MNKD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. MNKD Profitability Analysis

1.1 Basic Checks

  • MNKD had positive earnings in the past year.
  • In the past year MNKD had a positive cash flow from operations.
  • In multiple years MNKD reported negative net income over the last 5 years.
  • In multiple years MNKD reported negative operating cash flow during the last 5 years.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.85%, MNKD belongs to the top of the industry, outperforming 87.86% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 7.96%, MNKD belongs to the best of the industry, outperforming 92.10% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for MNKD is significantly below the industry average of 18.95%.
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROIC 7.96%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100 -150

1.3 Margins

  • The Profit Margin of MNKD (1.92%) is better than 88.25% of its industry peers.
  • Looking at the Operating Margin, with a value of 16.59%, MNKD belongs to the top of the industry, outperforming 92.68% of the companies in the same industry.
  • The Gross Margin of MNKD (77.80%) is better than 84.20% of its industry peers.
  • In the last couple of years the Gross Margin of MNKD has grown nicely.
Industry RankSector Rank
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

3

2. MNKD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MNKD is creating some value.
  • MNKD has more shares outstanding than it did 1 year ago.
  • MNKD has more shares outstanding than it did 5 years ago.
  • MNKD has a worse debt/assets ratio than last year.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • MNKD has an Altman-Z score of -4.28. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
  • MNKD has a Altman-Z score (-4.28) which is in line with its industry peers.
  • The Debt to FCF ratio of MNKD is 44.51, which is on the high side as it means it would take MNKD, 44.51 years of fcf income to pay off all of its debts.
  • MNKD has a better Debt to FCF ratio (44.51) than 88.44% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Altman-Z -4.28
ROIC/WACC0.93
WACC8.6%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • MNKD has a Current Ratio of 1.70. This is a normal value and indicates that MNKD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.70, MNKD is doing worse than 79.77% of the companies in the same industry.
  • A Quick Ratio of 1.50 indicates that MNKD should not have too much problems paying its short term obligations.
  • MNKD has a Quick ratio of 1.50. This is amonst the worse of the industry: MNKD underperforms 80.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.5
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

6

3. MNKD Growth Analysis

3.1 Past

  • The earnings per share for MNKD have decreased strongly by -28.75% in the last year.
  • MNKD shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.23%.
  • The Revenue has been growing by 39.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%

3.2 Future

  • MNKD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.44% yearly.
  • The Revenue is expected to grow by 17.70% on average over the next years. This is quite good.
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue Next Year36.86%
Revenue Next 2Y23.74%
Revenue Next 3Y16.07%
Revenue Next 5Y17.7%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 -1 -1.5

5

4. MNKD Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 38.00, the valuation of MNKD can be described as expensive.
  • 91.14% of the companies in the same industry are more expensive than MNKD, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 24.88, MNKD is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 42.81, the valuation of MNKD can be described as expensive.
  • MNKD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MNKD is cheaper than 90.37% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, MNKD is valued quite expensively.
Industry RankSector Rank
PE 38
Fwd PE 42.81
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 94.22% of the companies in the same industry are more expensive than MNKD, based on the Enterprise Value to EBITDA ratio.
  • 92.10% of the companies in the same industry are more expensive than MNKD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 51.32
EV/EBITDA 14.45
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • The decent profitability rating of MNKD may justify a higher PE ratio.
  • A more expensive valuation may be justified as MNKD's earnings are expected to grow with 65.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y91.27%
EPS Next 3Y65.59%

0

5. MNKD Dividend Analysis

5.1 Amount

  • MNKD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

MNKD Fundamentals: All Metrics, Ratios and Statistics

MANNKIND CORP

NASDAQ:MNKD (3/27/2026, 8:00:01 PM)

After market: 2.2865 +0.01 (+0.29%)

2.28

-0.02 (-0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners58.06%
Inst Owner Change3.51%
Ins Owners1.57%
Ins Owner Change2.58%
Market Cap702.47M
Revenue(TTM)348.97M
Net Income(TTM)6.70M
Analysts85.33
Price Target9.8 (329.82%)
Short Float %8.6%
Short Ratio4.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-116.48%
Min EPS beat(2)-439.47%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)-85.96%
Min EPS beat(4)-439.47%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-74.12%
EPS beat(12)5
Avg EPS beat(12)-38.6%
EPS beat(16)6
Avg EPS beat(16)-28.6%
Revenue beat(2)2
Avg Revenue beat(2)6.39%
Min Revenue beat(2)0.33%
Max Revenue beat(2)12.45%
Revenue beat(4)3
Avg Revenue beat(4)2.28%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)12.45%
Revenue beat(8)6
Avg Revenue beat(8)2.33%
Revenue beat(12)9
Avg Revenue beat(12)3.51%
Revenue beat(16)12
Avg Revenue beat(16)6.12%
PT rev (1m)0%
PT rev (3m)6.13%
EPS NQ rev (1m)-142.9%
EPS NQ rev (3m)-164.32%
EPS NY rev (1m)-38.97%
EPS NY rev (3m)-51.42%
Revenue NQ rev (1m)5.83%
Revenue NQ rev (3m)7.85%
Revenue NY rev (1m)9.02%
Revenue NY rev (3m)11.75%
Valuation
Industry RankSector Rank
PE 38
Fwd PE 42.81
P/S 2.01
P/FCF 51.32
P/OCF 38.48
P/B N/A
P/tB N/A
EV/EBITDA 14.45
EPS(TTM)0.06
EY2.63%
EPS(NY)0.05
Fwd EY2.34%
FCF(TTM)0.04
FCFY1.95%
OCF(TTM)0.06
OCFY2.6%
SpS1.13
BVpS-0.17
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.85%
ROE N/A
ROCE 9.32%
ROIC 7.96%
ROICexc 10.76%
ROICexgc 55.79%
OM 16.59%
PM (TTM) 1.92%
GM 77.8%
FCFM 3.92%
ROA(3y)1.74%
ROA(5y)-9.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.85%
ROIC(5y)N/A
ROICexc(3y)28.62%
ROICexc(5y)N/A
ROICexgc(3y)44.91%
ROICexgc(5y)N/A
ROCE(3y)12.18%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.37%
GM growth 5Y4.31%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.51
Debt/EBITDA 8.33
Cap/Depr 37.17%
Cap/Sales 1.31%
Interest Coverage 3.93
Cash Conversion 26.02%
Profit Quality 204.41%
Current Ratio 1.7
Quick Ratio 1.5
Altman-Z -4.28
F-Score5
WACC8.6%
ROIC/WACC0.93
Cap/Depr(3y)368.18%
Cap/Depr(5y)300.07%
Cap/Sales(3y)8.68%
Cap/Sales(5y)9.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-266.67%
EPS Next Y-6.55%
EPS Next 2Y91.27%
EPS Next 3Y65.59%
EPS Next 5Y52.44%
Revenue 1Y (TTM)22.23%
Revenue growth 3Y51.78%
Revenue growth 5Y39.91%
Sales Q2Q%45.82%
Revenue Next Year36.86%
Revenue Next 2Y23.74%
Revenue Next 3Y16.07%
Revenue Next 5Y17.7%
EBIT growth 1Y-18.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.06%
OCF growth 3YN/A
OCF growth 5YN/A

MANNKIND CORP / MNKD Fundamental Analysis FAQ

What is the fundamental rating for MNKD stock?

ChartMill assigns a fundamental rating of 5 / 10 to MNKD.


Can you provide the valuation status for MANNKIND CORP?

ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.


Can you provide the profitability details for MANNKIND CORP?

MANNKIND CORP (MNKD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of MANNKIND CORP (MNKD) stock?

The Price/Earnings (PE) ratio for MANNKIND CORP (MNKD) is 38 and the Price/Book (PB) ratio is -13.77.